← Back to Search

PD-1/CTLA-4 Bispecific Antibody

AK104 for Cervical Cancer

Phase 2
Waitlist Available
Research Sponsored by Akeso
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial will test how well AK104 works and how safe it is in treating cervical cancer that has come back or spread.

Eligible Conditions
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate (ORR) assessed by Independent Radiological Review Committee (IRRC)
Secondary outcome measures
Disease control rate (DCR)
Duration of Response (DoR)
Minimum observed concentration (Cmin) of AK104 at steady state
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AK104Experimental Treatment1 Intervention
AK104 monotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AK104
2019
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

AkesoLead Sponsor
100 Previous Clinical Trials
17,224 Total Patients Enrolled
Akesobio Australia Pty LtdIndustry Sponsor
9 Previous Clinical Trials
887 Total Patients Enrolled
Leslie Randall, MDStudy ChairVirginia Commonwealth University
1 Previous Clinical Trials
100 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
2020. "A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04380805.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top